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Abstract 
Background: The Sustainable Development Goals (SDG) call for increased gender equity and reduction in malaria-
related mortality and morbidity. Plasmodium vivax infections in pregnancy are associated with maternal anaemia and 
increased adverse perinatal outcomes. Providing radical cure for women with 8-aminoquinolines (e.g., primaquine) is 
hindered by gender-specific complexities.
Case presentation: A symptomatic episode of vivax malaria at 18 weeks of gestation in a primigravid woman was 
associated with maternal anaemia, a recurrent asymptomatic P. vivax episode, severe intra-uterine growth restriction 
with no other identifiable cause and induction to reduce the risk of stillbirth. At 5 months postpartum a qualitative 
glucose-6-phosphate dehydrogenase (G6PD) point-of-care test was normal and radical cure with primaquine was 
prescribed to the mother. A 33% fractional decrease in haematocrit on day 7 of primaquine led to further testing 
which showed intermediate phenotypic G6PD activity; the G6PD genotype could not be identified. Her infant daugh-
ter was well throughout maternal treatment and found to be heterozygous for Mahidol variant.
Conclusion: Adverse effects of vivax malaria in pregnancy, ineligibility of radical cure for pregnant and postpartum 
women, and difficulties in diagnosing intermediate levels of G6PD activity multiplied morbidity in this woman. Steps 
towards meeting the SDG include prevention of malaria in pregnancy, reducing unnecessary exclusion of women 
from radical cure, and accessible quantitative G6PD screening in P. vivax-endemic settings.
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Background
The Sustainable Development Goals (SDG) highlight 
freedom from the adverse effects of malaria (SDG 3.3) 
and gender equity (SDG 4) as global priorities for this 
decade. The intersection between health and gender 
equity has been recognized, and gender-specific inequi-
ties in the treatment and prevention of malaria have been 
a focus of recent quantitative and qualitative research 
[1]. Gender equity in health care requires not only equal 
access to health services, but also unequal access in 
response to unequal burden. In other words, one of the 
principles of gender equity requires that services for 
women not simply mirror services for men but differ 
from services for men in situations where women’s needs 
or disease processes differ [2].
The World Health Organization (WHO) estimated the 
global incidence of Plasmodium vivax to be 7.5 million 
cases in 2017, and it is the most prevalent malaria species 
in Southeast Asia [3]. Women and their fetuses uniquely 
suffer from the complications of malaria in pregnancy [4, 
5], including those associated with P. vivax infection [6].
Plasmodium vivax and Plasmodium ovale are the only 
two malaria species capable of relapses, due to the pres-
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known as hypnozoites. Treatment of the blood stages 
of acute vivax malaria relies on the schizontocidal agent 
chloroquine (CHQ) in most parts of the world, and is safe 
in pregnancy [7]. Relapse prevention is achieved with the 
8-aminoquinolines primaquine (PMQ) or tafenoquine 
(TQ), both active against P. vivax hypnozoites [7, 8] and 
contra-indicated in pregnancy as the glucose-6-phos-
phate dehydrogenase (G6PD) status of the fetus can-
not be determined antenatally in most malaria endemic 
settings.
The use of PMQ for radical cure is complicated by 
a few factors, including adherence to a 14-day course, 
commonly observed side effects such as abdominal pain 
and, specifically in G6PD-deficient individuals, the risk 
of drug-induced haemolysis [9–12]. TQ provides radical 
cure in a single dose, improving adherence, but has not 
yet been implemented widely since receiving approval 
from the US Food and Drug Administration (FDA) in 
2018 [13]. A major barrier to TQ roll-out is the poor 
sensitivity of common qualitative point-of-care tests to 
detect intermediate levels of G6PD deficiency in hete-
rozygote females who are at risk for haemolysis.
G6PD deficiency is caused by mutations of the G6PD 
gene, which is located on the X-chromosome; genotypes 
and phenotypic expression are different in males and 
females. Males are either hemizygous wild types (with 
a normal phenotype) or hemizygous mutated (with a 
deficient phenotype), and females can be homozygous 
mutated (with a deficient phenotype), homozygous 
wild type (with a normal phenotype) or heterozygous. 
The G6PD enzymatic activity of heterozygous females 
includes a spectrum of activity from partial deficiency to 
normal [14]. With qualitative G6PD rapid tests, patients 
can only be classified as deficient or normal according 
to the test threshold [15, 16]. As a result, heterozygous 
females with intermediate enzymatic activity are usually 
diagnosed as G6PD normal even though they are suscep-
tible to PMQ- and TQ-induced haemolysis [17]. If quali-
tative G6PD tests are done in the presence of anaemia or 
a haemolytic episode, false normal results are more likely, 
especially for heterozygote females [18]. Some point-of-
care quantitative G6PD tests have now been validated in 
laboratory settings [19, 20] but field validation for use in 
malaria case management has not yet been completed.
As there are no safe options for radical cure during 
pregnancy, the WHO conditionally recommends radical 
cure postpartum, after the infant has reached 6 months 
of age [7, 21]. On the Thailand-Myanmar border the 
strongest risk factor for P. vivax in the first 12 weeks post-
partum was a history of P. vivax infection during the pre-
vious 9 months [22]. Exclusion of pregnant and lactating 
females from radical cure potentially affects about 13% 
of females in malaria-endemic areas [6]. Providing PMQ 
postpartum for radical cure of P. vivax is essential in 
Southeast Asia because the majority of P. vivax infections 
are attributed to relapse [23, 24]. In the absence of timely 
radical cure, relapses may cause illnesses and anaemia in 
the postpartum period, and deleterious effects in a subse-
quent pregnancy, increasing the risk of maternal morbid-
ity (mostly due to anaemia), fetal loss (due to miscarriage 
and stillbirth) and neonatal mortality (due to pre-term 
birth, intra-uterine growth restriction (IUGR) and low 
birth weight) [4, 5, 25].
The aim of reporting this case is to describe the mul-
tiple gender-specific morbidities suffered by a woman 
infected with P. vivax during pregnancy and to discuss 
potential research and programmatic priorities that 




An 18-year-old, primigravid, pregnant Burman woman 
with an unremarkable medical history, presented to the 
antenatal care (ANC) clinic of Shoklo Malaria Research 
Unit (SMRU) on the Thailand-Myanmar border. She 
reported a 7-day history of fever, chills, rigour, headache, 
dizziness, occasional palpitations, general weakness as 
well as muscle and joint pain. She used an impregnated 
bed net nightly and denied having any previous malaria 
infection. Obstetric ultrasound examination confirmed 
a viable fetus with an estimated gestational age (EGA) 
of 18 weeks and 4 days. The peripheral blood smear was 
positive for P. vivax (Table 1).
Laboratory findings
Haematologic laboratory parameters on admission 
showed a haematocrit (HCT) of 31.2% and haemoglo-
bin of 10 g/dL. The reticulocyte count was elevated at 54 
per 1000 red blood cells (normal range 8–20) indicating 
increased erythropoiesis. Haemoglobin typing, G6PD 
fluorescent spot test (FST), oral glucose tolerance test 
were normal and VRDL, HIV and urine culture were 
negative.
Treatment
The patient consented to participate in a randomized, 
controlled, treatment trial (ClinicalTrials.gov Identi-
fier NCT01054248) and received an augmented regi-
men of artemether–lumefantrine (COA+) with 5 
tablets twice daily for 4  days (each dose contained 
100 mg/600 mg artemether/lumefantrine). As per WHO 
recommendations for pregnant women, PMQ was not 
given. Chloroquine chemoprophylaxis was not given 
Page 3 of 7Brummaier et al. Malar J           (2020) 19:40 
following treatment with COA+ as this was not in the 
trial protocol.
Parasitaemia cleared after 1 day of treatment and no 
fever was recorded on 6-hourly temperature measure-
ments. The patient was discharged on day 5. Since the 
HCT value on the day of discharge was only 27%, the 
patient was prescribed anaemia treatment (ferrous sul-
fate 400 mg twice daily and folic acid 5 mg once daily). 
The patient followed ANC once weekly for 63 days as 
per study protocol. Malarial screening was repeatedly 
negative and the HCT rose to 33% after 2  weeks of 
anaemia treatment.
Nearly 5 months later, at an estimated gestational age 
of 35 + 4 weeks, routine malaria screening by micros-
copy during the ANC visit detected P. vivax. She had 
no symptoms and was treated with CHQ (10  mg/kg 
per day for 2 days and 5 mg/kg per day for 1 day) fol-
lowing the standard treatment recommended by the 
WHO [7]. Parasites cleared after 2  days of CHQ and 
the HCT (35%) was normal. As with the first P. vivax 
episode, no prophylaxis was given.
Delivery
Routine symphysis fundal height measurement indicated 
poor fetal growth, which was confirmed by fetal anthro-
pometry using ultrasound. After induction of labour 
for severe IUGR, a normal female infant was birthed 
in an SMRU clinic with an estimated gestational age of 
38 + 6  weeks. The Apgar scores were 9 and 10 at 1 and 
5 min, respectively. On examination, small for gestational 
age (< 1st centile by international standards) was con-
firmed with a body weight of 1980 g, a head circumfer-
ence of 30 cm (< 3rd centile) and a body length of 45 cm 
(< 10th centile) [26]. Maternal, neonatal, umbilical cord, 
and placental blood smears were negative for malaria 
parasites. No risk factors other than the P. vivax episodes 
during pregnancy were identified for the severe IUGR.
Postpartum radical cure
After delivery the mother complied with study follow-
up visits and no more complications arose. At 5 months 
postpartum the young mother was planning to move to 
a remote region with limited access to adequate health 
care. Radical curative treatment with PMQ for P. vivax 
was recommended before she moved, given the risk of 
anaemia and poor outcome of a subsequent pregnancy, 
despite being 1 month short of the WHO recommenda-
tion at that time (2016) for lactating mothers of 6 months 
[7].
Before administration of PMQ, the mother and infant 
were tested for G6PD deficiency using a FST; both were 
confirmed phenotypically normal. At baseline, the moth-
er’s HCT was 41% [reticulocytes 3/1000 red blood cells 
(RBCs)] and the infant’s HCT was 36%; both blood slides 
were negative for P. vivax and the physical examination 
was unremarkable.
Daily weight-based treatment with PMQ (0.5  mg/kg/
day) for 14 days total was prescribed; the 4 tablets daily 
translated into an actual dose of 0.52 mg/kg/day (weight 
58 kg). The first dose was supervised in the clinic. At fol-
low-up on the 7th day none of the commonly observed 
PMQ side effects, such as abdominal pain, nausea or 
vomiting was reported [9] but the patient complained of 
dizziness. The HCT was 27.4% (reference range for non-
pregnant adult female 35.4–44.4%), an absolute reduction 
of 13.6% (from 41 to 27.4%), and equivalent to fractional 
reduction of 33%. Acute anaemia was confirmed with 
additional haematologic parameters and the patient was 
admitted for observation (Table 2).
Biochemistry showed normal kidney function and, 
apart from a mildly increased direct bilirubin (0.84 mg/
Table 1 Vital signs and  blood profiles at  the  first 
and second Plasmodium vivax episode
Reference ranges are shown in brackets and were adjusted to the corresponding 
trimester [38]
CHQ, Chloroquine; COA+, augmented regimen of artemether–lumefantrine (5 
tablets twice daily for 4 days); EGA, estimated gestational age; HB, haemoglobin; 
HCT, haematocrit; NA, not available; PVG, Plasmodium vivax gametocytes; PVT, 
Plasmodium vivax trophozoites; RBC, red blood cell count; WBC, white blood cell 
count
* HCT declined to 27% on day 5
1st episode 2nd episode
Schizontocidal treatment COA+ CHQ
EGA (weeks + days) 18 + 4 35 + 4
Maternal vital signs
 Heart rate (beats per minute) 70 92
 Blood pressure (mmHg) 110/60 120/80
 Respiratory rate (per minute) 24 23
 Body temperature (degree celsius) 38.8 36.1
 Weight (kg) 57 66
 Fetal heart rate (beats per minute) 148 152
 Fundal height (cm) 15 29
PVT (per µL) 340 478
PVG (per µL) 136 62
Parasite clearance (days) 1 2
RBC (× 106/μL) 3.63 (2.81–4.49) 4.0 (2.71–4.73)
HCT (%) 31.2* (30–39) 35.1 (28.0–40.0)
HB (g/dL) 10.0 (9.7–14.8) 11.9 (9.5–15.0)
Reticulocytes (%) 5.4 (0.8–2.0) NA
WBC (× 103/μL) 8.5 (5.6–14.8) 10.4 (5.9–16.9)
Platelets (× 103/μL) 245 (155–409) 217 (146–429)
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dL [normal range: 0.3–1.3]) and alkaline phosphatase 
(132 U/L [33–96]), normal liver function tests. At 236 
U/L (115–221) lactate dehydrogenase was slightly ele-
vated. The direct Coombs test was negative and there 
was no haemoglobinuria. Otherwise, history and physical 
examination were unremarkable.
Given the clinical picture, G6PD deficiency was sus-
pected despite the normal G6PD FST result as the FST 
has poor sensitivity to detect intermediate G6PD activity 
levels. The G6PD activity was then quantified by spectro-
photometry and was found to be normal at 7.7  IU/gHb 
(population median: 7.51 IU/gHb) [27], suggesting a false 
normal result in a haemolytic state (Hb 8.9 mg/dL).
The patient’s body weight was rechecked and found 
to be 56.5  kg. With no signs of severe haemolysis and 
no evidence of G6PD deficiency, the PMQ course was 
continued under supervision at a corrected dose of 3.5 
tablets daily (actual dose was 0.46  mg/kg/day for the 
remaining 7 days of treatment). The treatment was well 
tolerated from this point onwards and the woman’s clini-
cal condition improved. To treat the anaemia, the patient 
was provided with a 28-day course of ferrous sulfate, folic 
acid and vitamin B12. Since the mother was still breast-
feeding, the infant’s HCT was also followed and remained 
relatively stable (day 0, 4, 7 and 10 the HCT was 36, 38, 
33 and 33%, respectively, fractional reduction of 8%). On 
day 12 of PMQ, the maternal HCT had increased to 30%, 
symptoms had resolved, and the patient requested to be 
discharged home. 11 weeks later, the HCT was 37%, and 
the patient was well. The child’s vaccination schedule 
was completed, and the 6-month motor milestones were 
normal.
Additional laboratory findings following radical cure
Approximately 1 year after delivery, the mother returned 
with the infant for follow-up as part of the trial described 
earlier. Since the previous quantification of the G6PD 
activity during the haemolytic episode was considered 
unreliable (due to  increased reticulocyte count and low 
Hb level), the staff offered the woman to repeat quantita-
tive G6PD testing while in steady state (HCT 36.1%). This 
time the G6PD activity was found to be 4.62  IU/gHb, 
which corresponds to 62% of the population mean and 
is highly suggestive of G6PD heterozygosity [28]. Follow-
ing this new finding, the patient and infant were screened 
for the most common G6PD gene mutations seen in the 
area (Mahidol, Chinese-4, Viangchan, Mediterranean 
variants) [29]. The coding regions from exon 2 to exon 
13 of the G6PD gene of the mother were then sequenced 
according to protocol from Kim et al. [30] but no muta-
tion was found. Mutations in non-coding regions have 
been linked to deficient G6PD activity [31]; however, in 
this case no further investigations were pursued. Inter-
estingly the female infant was found to be heterozygous 
for the Mahidol variant. CYP2D6 genotyping was not 
performed but could have helped to clarify the haemo-
lytic pattern.
Conclusion
Recognizing gender-specific aspects of disease acquisi-
tion, detection, treatment options, and response to treat-
ment can help ensure that health policies are effective 
and equitable. As the historical legacy of gender-based 
inequality is deeply embedded in medical research and 
the health sector, action to prevent undue gender-specific 
disparities in health outcomes is an ethical imperative 
and mandated in the SDG [32].
In this case report of a female experiencing P. vivax in 
pregnancy, multiple layers of a gender-specific morbidity 
occur (Fig. 1). The reproductive impact of malaria is lim-
ited to females, and they suffer a double burden of more 
severe personal illness and poor outcomes for their off-
spring. The negative effect of P. vivax infection, especially 
Table 2 Blood results before, during, and after primaquine radical cure at 5 months postpartum
* Activity measured by spectrophotometry
Day 1 (before 
PMQ)
Day 4 Day 7 Day 10–12 11 weeks 7 months
HCT (35.4–44.4%) 41% – 27.4% 30% 37% 36.1%
Reticulocytes (per 1000 RBC) 3 – 40 – – –
RBC (4.00–5.20 × 106/μL) – – 3.14 – – –
Hb (12.0–15.8 g/dL) – – 8.9 – – 11.9
G6PD FST Normal – – – – –
G6PD activity* (IU/gHb) [% popula-
tion median]
– – 7.7 [103%] – – 4.62 [62%]
Infant HCT 36% 38% 33% 33% – 36%
Infant G6PD FST Normal – – – –
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recurrent infections, on birth weight has been demon-
strated, and this increases both short- and long-term 
morbidity and mortality for affected infants [5].
The second layer of a gender-specific morbidity 
results from the ineligibility of many females for radi-
cal cure due to their reproductive stage. It is estimated 
that about 13% of females with P. vivax are temporar-
ily ineligible for radical cure due to pregnancy or lac-
tation [6], and the proportion who eventually receive 
8-aminoquinolones postpartum as recommended by 
the WHO is unknown. Relapse is the main source of P. 
vivax infection in areas of low endemicity and contrib-
utes to chronic anaemia. A recent metanalysis confirms 
that, despite short term risk of haemolysis, radical cure 
with primaquine improves hematologic outcomes in 
the long term [33]. In most P. vivax-endemic regions, 
anaemia is a major public health problem, which con-
tributes to maternal mortality [34]. The only strategies 
currently available to prevent harm from recurrent 
vivax malaria in pregnancy are weekly chemoprophy-
laxis with CHQ in pregnant women following their 
first episode of malaria, as recommended by the WHO, 
and early detection and treatment. Compelling theo-
retical concerns of iatrogenic fetal anaemia or hydrops 
prevent the use of 8-amnioquinolones in pregnancy, 
but there are no actual reports of adverse pregnancy 
outcomes after inadvertent administration. A recent 
publication included a report of 52 women in Bra-
zil treated with primaquine during pregnancy (some 
repeatedly) without adverse birth outcomes [35]. How-
ever, G6PD testing was not done on the infants, and 
it is not unlikely that they were all G6PD normal. As 
other haemolytic drugs (eg. nitrofurantoin, dapsone) 
are used in pregnancy when indicated, it is conceiv-
able that 8-aminoquinolones could be used as well. 
However, establishing the safety of current or new 
hypnozoiticidal drugs would require a cautious and 
systematic approach, starting with in silica or ex-vivo 
models of trans-placental transfer. Establishing safety 
during breastfeeding is considerably more straightfor-
ward. Pharmacokinetic data suggest that the 6-month 
postpartum delay for primaquine is unnecessarily long 
as PMQ is excreted into mature breast milk in negli-
gible amounts [36]. Further information is needed on 
safety of PMQ in the neonatal period, and there is cur-
rently no data on TQ and lactation.  Information on 
8-aminoquinolones in the neonatal period are urgently 
needed as the opportune moment for radical cure is 
post-partum before the woman leaves the birth facility. 
Our  current institute policy is weekly chemoprophy-
laxis with CHQ until delivery after treatment of blood 
stages in women who experience a P. vivax infection, 
followed by radical cure with PMQ after 1-month post-
partum. Prior to discharge from the perinatal care unit, 
the patients are reminded of the significance of radical 
cure, and given a follow-up appointment.
The final layer of gender specific morbidity relates to 
tests for G6PD deficiency.  When females are not preg-
nant or breastfeeding and are eligible for 8-amino-
quinolones, they are at higher risk for misdiagnosis of 
G6PD deficiency by current qualitative testing [16]. This 
case involved a woman with only moderately decreased 
G6PD activity at 62% of the population mean, resulting 
in moderate but symptomatic haemolysis. It is expected 
that a fluorescent spot test (or an equivalent RDT) would 
classify heterozygous females with a G6PD activity as 
low as 30–40% as G6PD normal. In fact, Bancone et  al. 
found that 60% of G6PD heterozygous females were mis-
diagnosed by qualitative screening [28]. Due to the loss 
of G6PD-deficient cells to haemolysis during illness, 
heterozygote females with even less than 30–40% activ-
ity could be misdiagnosed as normal if the test is done 
Fig. 1 Comparison of timeline of Plasmodium vivax infection in this pregnant woman to a hypothetical male patient with Plasmodium vivax 
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during an acute P. vivax episode. Such a misdiagnosis 
could result in fatal haemolysis if 8-aminoquinolines are 
inappropriately prescribed to females with intermediate 
G6PD activity, which is an important consideration as 
the new single radical curative dose TQ has a long ter-
minal half-life. Field-validated point-of-care quantitative 
G6PD tests are an urgent priority to meet the ambitious 
WHO target of reducing malaria by 90% by the year 2030 
[37]. This is especially true in areas with high prevalence 
of G6PD deficiency in order to avoid iatrogenic morbid-
ity and mortality for females. Testing should be offered 
when individuals are healthy, such as at a preconception 
visit at the community level or during a routine antenatal 
care visit.
In this case the mother received PMQ while she con-
tinued to breastfeed a female infant with a G6PD het-
erozygous genotype (Mahidol variant) without adverse 
effects on the infant. Given the pharmacokinetics of 
primaquine during lactation and the dose-dependent 
nature of primaquine-induced haemolysis, it is very 
unlikely that the clinically insignificant 8% fractional 
reduction in HCT seen in this infant is due to drug 
exposure via breastmilk. However, the fact that she was 
classified as G6PD normal by FST further highlights 
the need for improved G6PD testing modalities.
Improving care and prevention of malaria in preg-
nancy, reducing unnecessary exclusion of women from 
radical cure, and providing quantitative G6PD screen-
ing that is as accurate for females as it is for males are 
achievable steps towards the SDG for a more equitable 
and malaria-free world.
Abbreviations
ALT: alanine aminotransferase; ANC: antenatal care; AST: aspartate aminotrans-
ferase; CHQ: chloroquine; COA+: augmented regimen of artemether–lume-
fantrine; EGA: estimated gestational age; FDA: food and drug administration; 
FST: fluorescent spot test; G6PD: glucose-6-phosphate dehydrogenase; HB: 
haemoglobin; HCT: haematocrit; IUGR : intra-uterine growth restriction; NA: 
not available; OD: once a day; PMQ: primaquine; PVG: Plasmodium vivax game-
tocytes; PVT: Plasmodium vivax trophozoites; RBC: red blood cell count; RDT: 
rapid diagnostic test; SDG: Sustainable Development Goals; SMRU: Shoklo 
Malaria Research Unit; TQ: Tafenoquine; WBC: white blood cell count; WHO: 
World Health Organization.
Acknowledgements
The Shoklo Malaria Research Unit is part of the Wellcome Trust Mahidol 
University Oxford Tropical Medicine Research Programme supported by the 
Wellcome Trust of Great Britain (Major Overseas Programme-Thailand Unit 
Core Gran: WT-106698).
Authors’ contributions
Conceptualization: TB, MEG, RM. Data curation: TB, MP, GG, GB. Formal analysis: 
TB, MEG, RM, CSC, GB. Investigation: GG, GB. Methodology: CSC, GB. Supervi-
sion: FN, RM. Validation: CSC, GB, KC, FN, RM. Writing—original draft: TB, MEG, 
RM. Writing—reviewing & editing: TB, MEG, GG, CSC, GB, MP, KC, FN, RM. 
The contributor’s roles listed above follow the Contributor Roles Taxonomy 
(CRediT) managed by The Consortia Advancing Standards in Research Admin-
istration Information (CASRAI) (https ://casra i.org/credi t/). All authors read and 
approved the final manuscript.
Funding
No specific grant from any funding agency in the public, commercial, or not-
for-profit sectors was received in preparation of this case report.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patient for publication of 
this case report. A copy of the written consent is available for review by the 
Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Author details
1 Shoklo Malaria Research Unit, Mahidol–Oxford Tropical Medicine Research 
Unit, Faculty of Tropical Medicine, Mahidol University, P.O. Box 46, 68/31 
Bann Tung Road, Mae Sot 63110, Thailand. 2 Swiss Tropical and Public Health 
Institute, Basel, Switzerland. 3 University of Basel, Basel, Switzerland. 4 Centre 
for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
University of Oxford, Old Road Campus, Oxford, UK. 5 Mahidol–Oxford Tropical 
Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 
Bangkok, Thailand. 
Received: 17 December 2019   Accepted: 13 January 2020
References
 1. Diiro GM, Affognon HD, Muriithi BW, Wanja SK, Mbogo C, Mutero C. The 
role of gender on malaria preventive behaviour among rural households 
in Kenya. Malar J. 2016;15:14.
 2. Braveman P, Gruskin S. Defining equity in health. J Epidemiol Community 
Health. 2003;57:254–8.
 3. WHO. World malaria report 2018. Geneva: World Health Organization, 
2018. https ://apps.who.int/iris/handl e/10665 /27586 7.
 4. Moore KA, Fowkes FJI, Wiladphaingern J, Wai NS, Paw MK, Pimanpanarak 
M, et al. Mediation of the effect of malaria in pregnancy on stillbirth and 
neonatal death in an area of low transmission: observational data analy-
sis. BMC Med. 2017;15:98.
 5. Moore KA, Simpson JA, Wiladphaingern J, Min AM, Pimanpanarak M, Paw 
MK, et al. Influence of the number and timing of malaria episodes during 
pregnancy on prematurity and small-for-gestational-age in an area of low 
transmission. BMC Med. 2017;15:117.
 6. Watson J, Taylor WRJ, Bancone G, Chu CS, Jittamala P, White NJ. Implica-
tions of current therapeutic restrictions for primaquine and tafenoquine 
in the radical cure of vivax malaria. PLoS Negl Trop Dis. 2018;12:e0006440.
 7. WHO. Guidelines for the treatment of malaria. 3rd Edn. Geneva: World 
Health Organization, 2015. http://www.ncbi.nlm.nih.gov/books /NBK29 
4440/.
 8. Watson J, Taylor WR, Menard D, Kheng S, White NJ. Modelling pri-
maquine-induced haemolysis in G6PD deficiency. ELife. 2017;6:e23061.
 9. Recht J, Ashley EA, White NJ. Safety of 8-aminoquinoline antimalarial 
medicines. Geneva: World Health Organization, 2014. http://www.who.
int/malar ia/publi catio ns/atoz/97892 41506 977/en/.
 10. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar 
J. 2014;13:418.
 11. Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, et al. 
Haemolysis in G6PD heterozygous females treated with primaquine for 
Plasmodium vivax malaria: a nested cohort in a trial of radical curative 
regimens. PLoS Med. 2017;14:e1002224.
 12. Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrit-
tayakamee S, et al. Directly-observed therapy (DOT) for the radical 14-day 
primaquine treatment of Plasmodium vivax malaria on the Thai–Myanmar 
border. Malar J. 2010;9:308.
Page 7 of 7Brummaier et al. Malar J           (2020) 19:40 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 13. White NJ. Tafenoquine—a radical improvement? N Engl J Med. 
2019;380:285–6.
 14. Beutler E, Yeh M, Fairbanks VF. The normal human female as a mosaic of 
X-chromosome activity: studies using the gene for G-6-PD-deficiency as 
a marker. Proc Natl Acad Sci USA. 1962;48:9–16.
 15. Ley B, Winasti Satyagraha A, Rahmat H, von Fricken ME, Douglas NM, 
Pfeffer DA, et al. Performance of the Access Bio/CareStart rapid diagnostic 
test for the detection of glucose-6-phosphate dehydrogenase deficiency: 
a systematic review and meta-analysis. PLoS Med. 2019;16:e1002992.
 16. Domingo GJ, Advani N, Satyagraha AW, Sibley CH, Rowley E, Kalnoky M, 
et al. Addressing the gender-knowledge gap in glucose-6-phosphate 
dehydrogenase deficiency: challenges and opportunities. Int Health. 
2019;11:7–14.
 17. Luzzatto L, Seneca E. G6PD deficiency: a classic example of phar-
macogenetics with on-going clinical implications. Br J Haematol. 
2014;164:469–80.
 18. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. 
G6PD testing in support of treatment and elimination of malaria: recom-
mendations for evaluation of G6PD tests. Malar J. 2013;12:391.
 19. Bancone G, Gornsawun G, Chu CS, Porn P, Pal S, Bansil P, et al. Validation 
of the quantitative point-of-care CareStart biosensor for assessment of 
G6PD activity in venous blood. PLoS ONE. 2018;13:e0196716.
 20. Alam MS, Kibria MG, Jahan N, Price RN, Ley B. Spectrophotometry assays 
to determine G6PD activity from Trinity Biotech and Pointe Scientific 
G6PD show good correlation. BMC Res Notes. 2018;11:855.
 21. WHO Malaria Policy Advisory Committee and Secretariat. Malaria Policy 
Advisory Committee to the WHO: conclusions and recommendations of 
eighth biannual meeting (September 2015). Malar J. 2016;15:117.
 22. Boel ME, Rijken MJ, Leenstra T, Phyo AP, Pimanpanarak M, Keereecharoen 
NL, et al. Malaria in the post-partum period; a prospective cohort study. 
PLoS ONE. 2013;8:e57890.
 23. Taylor AR, Watson JA, Chu CS, Puaprasert K, Duanguppama J, Day NPJ, 
et al. Resolving the cause of recurrent Plasmodium vivax malaria probabil-
istically. Nat Commun. 2019;10:1–11.
 24. Chu CS, Phyo AP, Lwin KM, Win HH, San T, Aung AA, et al. Comparison 
of the cumulative efficacy and safety of qhloroquine, artesunate, and 
chloroquine-primaquine in Plasmodium vivax malaria. Clin Infect Dis. 
2018;67:1543–9.
 25. Nosten F, McGready R, Simpson JA, Thwai KL, Balkan S, Cho T, et al. Effects 
of Plasmodium vivax malaria in pregnancy. Lancet. 1999;354:546–9.
 26. Villar J, Cheikh Ismail L, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. 
International standards for newborn weight, length, and head circumfer-
ence by gestational age and sex: the Newborn Cross-Sectional Study of 
the Intergrowth-21st Project. Lancet. 2014;384:857–68.
 27. Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak 
P, Charunwatthana P, et al. Suitability of capillary blood for quantitative 
assessment of G6PD activity and performances of G6PD point-of-care 
tests. Am J Trop Med Hyg. 2015;92:818–24.
 28. Bancone G, Gilder ME, Chowwiwat N, Gornsawun G, Win E, Cho WW, et al. 
Prevalences of inherited red blood cell disorders in pregnant women of 
different ethnicities living along the Thailand–Myanmar border. Wellcome 
Open Res. 2017;2:72.
 29. Bancone G, Chu CS, Somsakchaicharoen R, Chowwiwat N, Parker DM, 
Charunwatthana P, et al. Characterization of G6PD genotypes and 
phenotypes on the northwestern Thailand–Myanmar border. PLoS ONE. 
2014;9:e116063.
 30. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, et al. Performance of 
the CareStart G6PD deficiency screening test, a point-of-care diagnostic 
for primaquine therapy screening. PLoS ONE. 2011;6:e28357.
 31. Efferth T, Bachli EB, Schwarzl SM, Goede JS, West C, Smith JC, et al. 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency-type Zurich: a 
splice site mutation as an uncommon mechanism producing enzyme 
deficiency. Blood. 2004;104:2608.
 32. Gupta GR, Oomman N, Grown C, Conn K, Hawkes S, Shawar YR, et al. 
Gender equality and gender norms: framing the opportunities for health. 
Lancet. 2019;393:2550–62.
 33. Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, 
et al. The haematological consequences of Plasmodium vivax malaria 
after chloroquine treatment with and without primaquine: a WorldWide 
Antimalarial Resistance Network systematic review and individual patient 
data meta-analysis. BMC Med. 2019;17:151.
 34. McGready R, Boel M, Rijken MJ, Ashley EA, Cho T, Moo O, et al. Effect 
of early detection and treatment on malaria related maternal mortal-
ity on the north-western border of Thailand 1986–2010. PLoS ONE. 
2012;7:e40244.
 35. Pincelli A, Neves PAR, Lourenço BH, Corder RM, Malta MB, Sampaio-Silva J, 
et al. The hidden burden of Plasmodium vivax malaria in pregnancy in the 
Amazon: an observational study in Northwestern Brazil. Am J Trop Med 
Hyg 2018;99(1):73-83
 36. Gilder ME, Hanpithakphong W, Hoglund RM, Tarning J, Win HH, Hilda N, 
et al. Primaquine pharmacokinetics in lactating women and breastfed 
infant exposures. Clin Infect Dis. 2018;67:1000–7.
 37. WHO. Global technical strategy for malaria 2016–2030. Geneva:World 
Health Organization, 2015. http://www.who.int/malar ia/areas /globa 
l_techn ical_strat egy/en/.
 38. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and 
laboratory studies: a reference table for clinicians. Obstet Gynecol. 
2009;114:1326–31.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
